NASDAQ:ANGO - AngioDynamics Stock Price, Forecast & News

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) issued its quarterly earnings data on Tuesday, January, 7th. The medical instruments supplier reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.04. The medical instruments supplier had revenue of $70 million for the quarter, compared to the consensus estimate of $71.28 million. AngioDynamics had a return on equity of 3.72% and a net margin of 17.47%. The company's quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.22 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Tuesday, April 7th 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics issued an update on its FY20 earnings guidance on Tuesday, January, 7th. The company provided earnings per share (EPS) guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.13. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.85 million.

1 analysts have issued 1-year price targets for AngioDynamics' shares. Their forecasts range from $21.00 to $21.00. On average, they anticipate AngioDynamics' share price to reach $21.00 in the next year. This suggests a possible upside of 35.7% from the stock's current price. View Analyst Price Targets for AngioDynamics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

News stories about ANGO stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AngioDynamics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for AngioDynamics.

AngioDynamics saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,350,000 shares, an increase of 35.0% from the December 15th total of 1,000,000 shares. Based on an average daily volume of 338,800 shares, the days-to-cover ratio is presently 4.0 days. Currently, 3.7% of the company's shares are short sold. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Intel (INTC), General Electric (GE), Oasis Petroleum (OAS), Cal-Maine Foods (CALM), FireEye (FEYE), Mattel (MAT), Bank of America (BAC), Centurylink (CTL), Hanesbrands (HBI) and Marathon Oil (MRO).

AngioDynamics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (1.73%), Assenagon Asset Management S.A. (0.76%), First National Bank of Omaha (0.11%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for AngioDynamics.

ANGO stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and First National Bank of Omaha. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $15.48.

AngioDynamics has a market capitalization of $582.51 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]